Financial Daily from THE HINDU group of publications
Saturday, Oct 15, 2005


News
Features
Stocks
Shipping
Archives
Google

Group Sites

Home Page - Pharmaceuticals
Corporate - Outlook
Industry & Economy - Health


Cipla to launch generic drug for bird flu

P.T. Jyothi Datta

Mumbai , Oct. 14

CIPLA has done it again. As more countries report incidents of Avian flu, the Mumbai-based drug maker Cipla has said that it will be ready with generic versions of Roche's anti-influenza drug Tamiflu by the year-end.

"Cipla has developed the generic version of the drug, but we will honour the patent (on the drug) in countries where it is valid. Where it is not valid, the situation does not arise," the Cipla Chief, Dr Yusuf Hamied, currently in Spain, told Business Line.

Tamiflu is an anti-viral drug used to treat bird-flu and Cipla's announcement comes as governments stockpile the drug fearing an epidemic. Swiss drugmaker Roche is under pressure to step up supplies of Tamiflu, as fears of a shortage of the drug fanned across countries.

The last time around Cipla stirred up global markets was in 2001, when it offered its anti-AIDS drugs for African patients.

Dr Hamied said that his interest in having a generic version of Tamiflu was sparked by the concern that India was unprepared. "What happens if there is an emergency in India? It has hit Turkey. If it hits India it will make the earthquake in Pakistan and Kashmir look like a tea-party. This is a serious situation; I hope there is no epidemic. But what I am saying is a warning alarm. India should be prepared," he said.

Unwilling to be drawn into committing on price, he said, "It will be a humanitarian price." Ten tablets sell at $60 in the US, at 30 in England and even in tenders, the price of the drug is quoted at $30 for 10 tablets, he said. But then again, he adds, "Price is secondary, availability is critical."

No Government in India or from any other region has approached Cipla yet for the drug, he said. "We have sent a message to WHO (World Health Organisation). We will work within the parameters of the patent," he said, indicating that the company would not target the US and Europe, unless asked by governments.

"We will manufacture the drug and keep it for an emergency," he said, reiterating that the drug was being developed with a humanitarian view.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Tata Safari Dicor

Stories in this Section
`Low' crosses land; rain belt moving northward


Teles India router `helps cos cut phone bills'
Costlier food, energy rates push up inflation
Gas shortage leaves power utilities struggling
GAIL scouting for equity partners for Nabuko project
Cipla to launch generic drug for bird flu
H-1B visa holders being paid lower wages, says US tech workers' group
Bank stocks pull down market; Sensex sheds 175 points
Citigroup to focus on organic growth — Dedicates financial literacy centre to Indian School of Microfinance for Women


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line